Drug major Industries on Monday said it has acquired three anti-inflammatory brands—Disperzyme, Disperzyme-CD, and Phlogam—from Mumbai-based Aksigen Hospital Care.
All the brands are approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures, Sun Pharma said in a statement.
The company, however, did not disclose the financial details of the transaction.
Disperzyme and Phlogam are the first enzyme-bioflavonoid combinations of Trypsin, Bromelain, and Rutoside to complete a clinical study in India and get DCGI approval.
The brands were registered and launched in India by Aksigen in 2013.
“The addition of Disperzyme and Phlogam further strengthens our anti-inflammatory portfolio. This systemic enzyme therapy combination is used to control oedema and it speeds up the healing process,” it said.
“In a comparative clinical trial in India, the brands provided significantly better control and resolution of postoperative pain and inflammation,” Sun Pharma India business CEO Kirti Ganorkar said.
As per IQVIA data, India’s overall market of proteolytic enzymes for healing, pain, and oedema is estimated to be around Rs 500 crore.
![Read more about the article [Weekly funding roundup Sept 19-23] Venture capital inflow sees a decline](https://blog.digitalsevaa.com/wp-content/uploads/2022/04/weekly-funding-roundup-1640354161359-300x150.png)
